27.7 USD
+0.34 (+1.24%)
27.7 USD
0 (0%)
Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 192 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth This makes AMPH very considerable for value investing!
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
Each year in the past 5 years AMPH has been profitable.
Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
AMPH's Return On Assets of 6.70% is amongst the best of the industry. AMPH outperforms 88.54% of its industry peers.
AMPH's Return On Equity of 14.37% is amongst the best of the industry. AMPH outperforms 89.06% of its industry peers.
The Return On Invested Capital of AMPH (8.51%) is better than 86.98% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 12.71%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
AMPH has a Profit Margin of 15.43%. This is amongst the best in the industry. AMPH outperforms 88.02% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 20.73%, AMPH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
The Gross Margin of AMPH (49.36%) is better than 63.02% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
The number of shares outstanding for AMPH has been increased compared to 5 years ago.
The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.44 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
AMPH has a better Altman-Z score (2.44) than 63.54% of its industry peers.
AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.49, AMPH belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
The Debt to Equity ratio of AMPH (0.78) is worse than 69.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.44 |
ROIC/WACC1
WACC8.53%
2.3 Liquidity
A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio (3.12) which is comparable to the rest of the industry.
AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AMPH (2.21) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -0.03%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
The Earnings Per Share is expected to grow by 0.14% on average over the next years.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.14% yearly.
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.14%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.14%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMPH is valuated reasonably with a Price/Earnings ratio of 8.05.
Compared to the rest of the industry, the Price/Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 92.19% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, AMPH is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.44, the valuation of AMPH can be described as very cheap.
AMPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 92.71% of the companies in the same industry.
AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.05 | ||
| Fwd PE | 7.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 91.15% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 88.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.47 | ||
| EV/EBITDA | 7.63 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.7
+0.34 (+1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners71.91%
Inst Owner Change0.4%
Ins Owners9.28%
Ins Owner Change3.46%
Market Cap1.27B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target33.05 (19.31%)
Short Float %11.87%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-2.41%
PT rev (3m)0%
EPS NQ rev (1m)3%
EPS NQ rev (3m)-0.31%
EPS NY rev (1m)-0.38%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)-1.61%
Revenue NQ rev (3m)-3.37%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.05 | ||
| Fwd PE | 7.44 | ||
| P/S | 1.76 | ||
| P/FCF | 11.47 | ||
| P/OCF | 8.36 | ||
| P/B | 1.64 | ||
| P/tB | 6.22 | ||
| EV/EBITDA | 7.63 |
EPS(TTM)3.44
EY12.42%
EPS(NY)3.72
Fwd EY13.45%
FCF(TTM)2.42
FCFY8.72%
OCF(TTM)3.31
OCFY11.96%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.44 |
F-Score5
WACC8.53%
ROIC/WACC1
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-1.68%
EBIT Next 3Y1.08%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -11.92% in the next year.